Long-term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function

No abstract is available for this paper.

• Publication year

  2001

• Venue

  American Journal of Gastroenterology

• Publication date

  2001-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1572-0241.2001.03636.xPMID 11316178
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Cisapride does not modify prolonged Q-T interval in patients with liver cirrhosis].

  2000cited by this paper
• La cisaprida no altera el intervalo Q-T prolongado en pacientes con cirrosis hepática

  2000cited by this paper
• Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis

  2000cited by this paper
• Orthotopic liver transplantation improves small bowel motility disorders in cirrhotic patients.

  1997cited by this paper
• Altered Small Bowel Motility in Patients with Liver Cirrhosis Depends on Severity of Liver Disease

  1997cited by this paper
• Gastrointestinal dysfunction in liver disease and portal hypertension. Gut-liver interactions revisited.

  1996cited by this paper
• Abnormal intestinal motor patterns explain enteric colonization with gram-negative bacilli in late radiation enteropathy.

  1995cited by this paper
• Gastrointestinal transit in cirrhotic patients: Effect of hepatic encephalopathy and its treatment

  1994cited by this paper
• Abnormalities in proximal small bowel motility in patients with cirrhosis

  1993cited by this paper
• [Morphology of the myenteric plexus of the small intestine in patients with liver cirrhosis].

  1993cited by this paper
• [Patients with liver cirrhosis: mouth-cecum transit time and gastric emptying of solid foods].

  1991cited by this paper
• [Bacterial overgrowth in small intestine in patients with liver cirrhosis].

  1991cited by this paper
• Intestinal endotoxins as mediators of hepatic injury—An idea whose time has come again

  1989cited by this paper
• Alterations of myoelectric activity associated with Campylobacter jejuni and its cell-free filtrate in the small intestine of rabbits.

  1985cited by this paper
• Jejunal manometry patterns in health, partial intestinal obstruction, and pseudoobstruction.

  1983cited by this paper
• Myoelectric effects of Clostridium difficile: motility-altering factors distinct from its cytotoxin and enterotoxin in rabbits.

  1982cited by this paper
• The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine.

  1977cited by this paper
• The bacterial content of the small intestine in normal and cirrhotic subjects: relation to methionine toxicity.

  1957cited by this paper

• The Emerging Challenge of Non-Cirrhotic MASLD-Related Hepatocellular Carcinoma: Etiology, Immunopathology, and Precision Oncology.

  2025cites this paper
• Comparative efficacy of diverse therapeutic regimens for small intestinal bacterial overgrowth: a systematic network meta-analysis

  2025cites this paper
• Common questions and rationale answers about the intestinal bacterial overgrowth syndrome (SIBO)

  2024cites this paper
• Pathogenesis and management of metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma: a narrative review

  2024cites this paper
• The effect of propranolol on gastrointestinal motility and permeability in patients with cirrhosis and significant portal hypertension

  2024cites this paper
• [SIBO, from myth to reality].

  2024cites this paper
• Small Intestinal Bacterial Overgrowth

  2024cites this paper
• Small intestinal bacterial overgrowth – current, novel and possible future methods of treatment and diagnosis

  2024cites this paper
• Preguntas Comunes Y Respuestas Razonadas Sobre El Síndrome Del Sobrecrecimiento Bacteriano Intestinal (SIBO)

  2024cites this paper
• Implications of Microbiota and Immune System in Development and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease

  2024cites this paper
• Morphological variation of Oreochromis niloticus (Lacépède, 1803) populations in stressed environment: Middle stream of Comoé River (Ivory Coast)

  2024cites this paper
• Effect of Trimebutine and Rifaximin on Breath Hydrogen and Methane by Glucose Breath Test in Patients With Functional Bloating: A Randomized Double-blind Clinical Trial.

  2024cites this paper
• Gut-liver Axis: Recent concepts in pathophysiology in alcohol-associated liver disease.

  2024cites this paper
• Intestinal microbiome-targeted therapies improve liver function in alcohol-related liver disease by restoring bifidobacteria: a systematic review and meta-analysis

  2024cites this paper
• Alcohol and the mechanisms of liver disease

  2023cites this paper
• Rifaximin Improves Liver Functional Reserve by Regulating Systemic Inflammation

  2023cites this paper
• Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment

  2023cites this paper
• Chronic Exposure to Environmentally Relevant Concentrations of Tetracycline Perturbs Gut Homeostasis in Zebrafish

  2023cites this paper
• Gastrointestinal Tract Considerations: Part II: How Should a Rheumatologist Best Manage Common Lower Gastrointestinal Tract Complaints in Systemic Sclerosis?

  2023cites this paper
• Gut microbiota-modulating agents in alcoholic liver disease: Links between host metabolism and gut microbiota

  2022cites this paper
• Elevation of enterococcus-specific antibodies associated with bacterial translocation is predictive of survival rate in chronic liver disease

  2022cites this paper
• Research Progress of Probiotics in the Treatment of Nonalcoholic Fatty Liver Disease

  2022cites this paper
• Liver cirrhosis and immune dysfunction.

  2022cites this paper
• Efficacies of prokinetics and rifaximin on the positivity to glucose breath test in patients with functional dyspepsia: randomized trial.

  2022cites this paper
• Crosstalk between PPARs and gut microbiota in NAFLD.

  2021cites this paper
• Gut Microbiota and the Liver: Interaction Shaping Interactome

  2021cites this paper
• The Role of Gut Microbiota Dysbiosis in Gastrointestinal Carcinogenesis

  2021cites this paper
• The effectiveness of rotating versus single course antibiotics for small intestinal bacterial overgrowth

  2021cites this paper
• NON-ALCOHOLIC FATTY LIVER DISEASE IN THE CONTEXT OF ALTERED GUT MICROBIOTA.

  2021cites this paper
• Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors

  2021cites this paper
• New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease

  2021cites this paper
• Risk Factors for Renal Impairment in Adult Patients With Short Bowel Syndrome

  2021cites this paper
• Gut microbiota and immune system in liver cancer: Promising therapeutic implication from development to treatment

  2021cites this paper
• Microbiota, Bacterial Carbonic Anhydrases, and Modulators of Their Activity: Links to Human Diseases?

  2021cites this paper
• Gastrointestinal Health

  2021cites this paper
• Green Plant Pigment, Chlorophyllin, Ameliorates Non-alcoholic Fatty Liver Diseases (NAFLDs) Through Modulating Gut Microbiome in Mice

  2021cites this paper
• Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma

  2020cites this paper
• ÄÓ «Íàö3îíàëüíèé 3íñòèòóò òåðàï3¿ 3ì. Ë.Ò. Ìàëî¿ ÍÀÌÍ Óêðà¿íè», ì. Õàðê3â

  2020cites this paper
• The Role of Gut Microbiota in Host Lipid Metabolism: An Eye on Causation and Connection

  2020cites this paper
• Small Intestinal Bacterial Overgrowth: How to Diagnose and Treat (and Then Treat Again).

  2020cites this paper
• MICROBIOTA REPROGRAMMING FOR TREATMENT OF ALCOHOL-RELATED LIVER DISEASE.

  2020cites this paper
• Microbiota and alcohol use disorder: are psychobiotics a novel therapeutic strategy?

  2020cites this paper
• Small intestinal bacterial and fungal overgrowth

  2020cites this paper
• Combination of Probiotics and Salvia miltiorrhiza Polysaccharide Alleviates Hepatic Steatosis via Gut Microbiota Modulation and Insulin Resistance Improvement in High Fat-Induced NAFLD Mice

  2019cites this paper
• Small Intestinal Bacterial Overgrowth: Clinical Features and Therapeutic Management

  2019cites this paper
• Infections in cirrhotic patients

  2019cites this paper
• New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer.

  2019cites this paper
• Microbiome dysbiosis and alcoholic liver disease☆

  2019cites this paper
• The Dirty Side of Colonoscopy: Predictors of Poor Bowel Preparation and Novel Approaches to Overcome the Shortcomings

  2019cites this paper
• Small Intestinal Bacterial Overgrowth in Patients With Cirrhosis.

  2019cites this paper
• The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD)

  2019cites this paper
• Are Probiotics Effective in Targeting Alcoholic Liver Diseases?

  2019cites this paper
• Microbiota, Inflammation, and Gut Barrier Dysfunction in HCC

  2019cites this paper
• Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta-analysis.

  2018cites this paper
• Use of prokinetic agents or antibiotics is associated with the occurrence of spontaneous bacterial peritonitis in cirrhotic patients

  2018cites this paper
• Microbiota, Obesity and NAFLD.

  2018cites this paper
• Is psoriasis a bowel disease? Successful treatment with bile acids and bioflavonoids suggests it is.

  2018cites this paper
• Small Bowel Transit and Altered Gut Microbiota in Patients With Liver Cirrhosis

  2018cites this paper
• The Role of the Bacterial Microbiota in Alcoholic and Non-alcoholic Fatty Liver Disease

  2018cites this paper
• The role of the microbiome in NAFLD and NASH

  2018cites this paper
• Small intestinal bacterial overgrowth in cirrhosis: systematic review and meta-analysis

  2018cites this paper
• Mosapride Stabilizes Intestinal Microbiota to Reduce Bacterial Translocation and Endotoxemia in CCl4-Induced Cirrhotic Rats

  2017cites this paper
• Роль микробиоты кишечника в патогенезе дислипидемии и ассоциированных метаболических нарушений

  2017cites this paper
• The gut microbiome and liver cancer: mechanisms and clinical translation

  2017cites this paper
• Small Intestinal Bacterial Overgrowth: Nutritional Implications, Diagnosis, and Management.

  2017cites this paper
• Systematic Review and Meta-Analysis: Prevalence of Small Intestinal Bacterial Overgrowth in Chronic Liver Disease

  2017cites this paper
• 'Targeting the gut-liver axis in liver disease' Clinical Trial Watch

  2017cites this paper
• Chronic intestinal pseudo‐obstruction in children and adults: diagnosis and therapeutic options

  2017cites this paper
• Gastrointestinal Motility Disorders and Their Clinical Implications in Cirrhosis

  2017cites this paper
• Targeting the gut-liver axis in liver disease.

  2017cites this paper
• Targeting the gut barrier for the treatment of alcoholic liver disease.

  2017cites this paper
• The Gut Microbiome and Cirrhosis: Basic Aspects

  2016cites this paper
• Non-alcoholic fatty liver and the gut microbiota

  2016cites this paper
• Gut Microbiota and Alcoholic Liver Disease.

  2016cites this paper
• Diagnosis and treatment of small intestinal bacterial overgrowth

  2016cites this paper
• Novel prevention strategies for bacterial infections in cirrhosis

  2016cites this paper
• Microbiota-based treatments in alcoholic liver disease.

  2016cites this paper
• PREBIÓTICOS Y PROBIÓTICOS: MECANISMOS DE ACCIÓN Y SUS APLICACIONES CLÍNICAS

  2016cites this paper
• Liver disease: interactions with the intestinal microbiota

  2016cites this paper
• How to Test and Treat Small Intestinal Bacterial Overgrowth: an Evidence-Based Approach

  2016cites this paper
• Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis.

  2015cites this paper
• Alcoholic liver disease: the gut microbiome and liver cross talk.

  2015cites this paper
• Small Intestinal Bacterial Overgrowth

  2015cites this paper
• Gastrointestinal Dysfunction in Chronic Liver Disease

  2015cites this paper
• Review article: alcohol and gut microbiota ‐ the possible role of gut microbiota modulation in the treatment of alcoholic liver disease

  2015cites this paper
• Changes in gut bacterial populations and their translocation into liver and ascites in alcoholic liver cirrhotics

  2014cites this paper
• Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013.

  2014cites this paper
• Infectious Microecology in Liver Disease

  2014cites this paper
• Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites

  2014cites this paper
• Probiotic as a Novel Treatment Strategy Against Liver Disease

  2013cites this paper
• Targeting the Gut–Liver Axis in Cirrhosis: Antibiotics and Non-Selective β-Blockers

  2013cites this paper
• Review article: small intestinal bacterial overgrowth – prevalence, clinical features, current and developing diagnostic tests, and treatment

  2013cites this paper
• Small Intestinal Bacterial Overgrowth

  2013cites this paper
• Small intestinal bacterial overgrowth and delayed orocecal transit time in patients with cirrhosis and low-grade hepatic encephalopathy

  2013cites this paper
• Deficiency of intestinal mucin‐2 ameliorates experimental alcoholic liver disease in mice

  2013cites this paper
• Erythromycin versus neomycin in the treatment of hepatic encephalopathy in cirrhosis: a randomized double-blind study

  2013influential citation
• The anti-inflammatory and antioxidant properties of Kenyan leafy green vegetables, wild fruits, and medicinal plants: relation of the health-promoting properties of biodiversity to contribute to kwashiorkor alleviation

  2012cites this paper
• Bacterial translocation and changes in the intestinal microbiome associated with alcoholic liver disease.

  2012cites this paper
• Rifaximin reduces endotoxemia and improves liver function and disease severity in patients with decompensated cirrhosis

  2012cites this paper
• Histological discrimination between autoimmune hepatitis and drug‐induced liver injury

  2012cites this paper